OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor Failure; Checkpoint Inhibitor Failures Is an Unmet Need in Non-Small Cell Lung Cancer Patient Population…